0.55
+0.0049(+0.89%)
Currency In USD
Address
2051 Ringwood Avenue
San Jose, CA 95131
United States of America
Phone
408 457 3700
Sector
Healthcare
Industry
Biotechnology
Employees
105
First IPO Date
July 30, 2021
| Name | Title | Pay | Year Born |
| Mr. Talat Imran | Chief Executive Officer & Director | 105,818 | 1982 |
| Mr. Mir A. Imran | Executive Chairman | 40,000 | 1957 |
| Dr. Mir Hashim | Chief Scientific Officer | 416,000 | 1960 |
| Mr. Svai S. Sanford | Chief Financial Officer | 416,000 | 1970 |
| Ms. Bella Vazquez | Vice President of Human Resources | 0 | N/A |
| Mr. Eric Groen J.D. | General Counsel | 0 | 1971 |
| Ms. Arvinder Dhalla | Vice President of Clinical Development | 0 | N/A |
| Mr. Alireza Javadi | Vice President of Technical Operations | 0 | N/A |
| Ms. Kate McKinley M.B.A. | Chief Business Officer | 0 | 1977 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.